Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 386-394

  Braun, Marina ^a   Elshoff, Jan Peer ^a   Andreas, Jens Otto ^a   Müller, Louise Ischen ^b   Horstmann, Rolf ^a  

^a Schwarz Pharma AG   (Germany)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

Drug drug interaction; Oral contraceptives; Ovulation suppression; Pharmacodynamics; Pharmacokinetics; Rotigotine transdermal patch

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE; ROTIGOTINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OVULATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TRANSDERMAL PATCH; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; OVULATION INHIBITION; PROGESTERONE; TETRAHYDRONAPHTHALENES; THIOPHENES; YOUNG ADULT;

EID: 69949165462     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03468.x     Document Type: Article

References (19)

1. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005 65 (Suppl. 1 S3 5.
2. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 68 : 272 276. (Pubitemid 46148338)
3. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 6 : 513 520.
4. Oertel WH, Beneš H, García-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008 9 : 228 239.
5. Trenkwalder C, Beneš H, Poewe W, Oertel WH, García- Borreguero D, de Weerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008 7 : 595 604.
6. 14C]-rotigotine by a patch formulation. A mass balance trial. Clin Pharmacokinet 2007 46 : 851 857.
7. Reynolds NA, Wellington K, Easthope SE. Rotigotine. In Parkinson's disease. CNS Drugs 2005 19 : 973 981.
8. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine. J Clin Pharmacol 2005 45 : 1091.
9. Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995 28 : 203 215.
10. Back DJ, Breckenridge AM, Crawford FE. An investigation of the pharmacokinetics of ethinylestradiol in women using radioimmunoassay. Contraception 1979 20 : 263 273.
11. Zhang H, Cui D, Wang B, Han Y-H, Balimane P, Yang Z, Sinz M, Rodrigues AD. Pharmacokinetic drug interactions involving 17α-ethinylestradiol. A new look at an old drug. Clin Pharmacokinet 2007 46 : 133 157.
12. Shenfield GM. Oral contraceptives. Are drug interactions of clinical significance? Drug Safety 1993 9 : 21 37.
13. García-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006 10 : 153 167. (Pubitemid 43817594)
14. U.S. Food and Drug Administration. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products. 99D-0236, 1999.
15. Thomas L. Laboratory and Diagnosis, 6th Edn. Frankfurt/Main : TH/Books Verlagsgesellschaft mbH, 2005 (in German).
16. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999 181 : 1263 1269.
17. Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009 67 : 209 215.
18. Kvernmo T, Härtter S, Bürger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006 28 : 1065 1078.
19. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000 39 : 243 254.